| |
|
SHS Newsletter – To open this newsletter in your browser, please click here.
|
| |
|
|
|
| |
February 2020
|
 |
|
|
|
| |
| |
|
Dear Sir or Madam,
|
| |
The year 2020, for which we wish you all the best, has gotten off to a turbulent start: the United Kingdom left the European Union a few days ago, and a variety of geopolitical hot spots, in addition to trade conflicts, are contributing to global economic uncertainty.
But despite these difficult conditions, we remain optimistic realists at SHS and have interesting news to report in the first newsletter of the year. In an interview with medtech zwo magazine, we continue to see investment opportunities in a dynamic sector that may be losing some momentum, but is also experiencing a boost as a result of the digital transformation.
With Selfapy GmbH, we present you with a new portfolio company that occupies a prominent market position in online psychotherapy. Tyromotion GmbH produces high-tech rehabilitation equipment for patients with Parkinson’s disease and strokes and is continuing to post successes. After a year of field testing, CoreMedic has only positive things to report about ChordArt, its mitral valve implant.
We also report on successful conference attendance by our colleagues in London and San Francisco.
I wish you an enjoyable read!
|
| |
|
| |
|
Hubertus Leonhardt
|
|
|
.jpeg)
|
| |
| |
|
Topics
|
| |
| • |
“We see investment opportunities for us”
|
| |
|
|
|
| • |
Digital health as a growth market: SHS invests in Selfapy
|
| |
|
|
| • |
Neurology clinic relies on Tyromotion
|
| |
|
|
| • |
CoreMedic convinces: ChordArt mitral valve repair system flawless in 12-month test
|
| |
|
|
|
| • |
David Wehner: Senior Investment Manager with entrepreneurial background
|
| |
|
|
| • |
Farewell to founding partner Reinhilde Spatscheck
|
| |
|
|
| • |
J.P. Morgan Healthcare Conference in San Francisco – January 2020
|
| |
|
|
| • |
Sascha Alilovic of SHS on the London podium on the topic of “Exits in Medtech Investments”
|
| |
|
|
|
| • |
Jobs at Portfolio Companies
|
| |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
“We see investment opportunities for us” |
|
|
| |
| |
|
|
In an interview with the specialist magazine medtech zwo, Hubertus Leonhardt, Managing Director and Partner at SHS, presents the new SHS Medical Technology Index, which can be used to map and substantiate industry trends in figures. The index was developed in cooperation with Prof. Dr. Christian Koziol (Head of the Department of Finance at the University of Tübingen). While the index currently shows a slowdown in growth, we recommend that mid-market players in medical devices take advantage of opportunities with active forward strategies.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Digital health as a growth market: SHS invests in Selfapy |
|
|
| |
| |
 |
| |
| Selfapy founders (from left to right) Katrin Bermbach, Farina Schurzfeld and Nora Blum |
|
|
|
The digital transformation in the healthcare industry is an outstanding trend, and, according to the experts, offers great growth potential. As part of a capital increase, we invested in Berlin-based Selfapy GmbH, Germany’s leading provider of online therapies for stress and psychological issues. With the capital provided, this dynamic company will drive its national and international expansion, consistently further develop the product and undertake additional clinical validations of its online therapy platform. The existing cooperation arrangements with 16 health insurance companies in Germany, Austria and Switzerland attest to the acceptance of the online therapy offerings of Selfapy. You are also encouraged to read our latest press release on this topic.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2016
Business purpose: Provider for online therapies for mental health
Products: Online therapy programs that are based on cognitive behavioral therapy, for stress symptoms, depression, and anxiety and eating disorders
Location: Berlin (D)
|
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Neurology clinic relies on Tyromotion |
|
|
| |
| |
The Sorpesee Neurological Clinic (NKS) in Germany’s Sauerland region specializes in the treatment of Parkinson’s, multiple sclerosis and patients with pain. The clinic has selected technology-assisted rehabilitation equipment by Tyromotion and benefits from this unique selling point over other facilities.
|
|
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2007
Business purpose: Development and distribution of robot-assisted and computer-assisted therapeutic devices for the rehabilitation sector, primarily for stroke patients
Products: Amadeo finger-hand-therapy, Diego arm-rehabilitation, Myro interactive therapy, Pablo hand-arm-Rehabilitation, Tymo therapy board, Lexo Gait-Training, Omego Pre Gait Therapy
Location: Graz (A)
|
|
| |
|
|
|
|
|
| |
| |
|
|
| |
CoreMedic convinces: ChordArt mitral valve repair system flawless in 12-month test |
|
|
| |
| |
|
|
At the Transcatheter Cardiovascular Therapeutics (TCT) convention in 2019 in San Francisco (US), Prof. Dr. Gorav Ailawadi (University of Virginia) presented the results of a study of the repair system for heart valves by SHS portfolio company CoreMedic AG.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2012
Business purpose: Development of devices and therapies to address the treatment of heart valve diseases: repair system that replaces ruptured or elongated chordae tendineae by applying a minimally invasive approach
Product: ChordArtTM System
Locations: Radolfzell (D), Biel (CH) |
|
| |
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
David Wehner: Senior Investment Manager with entrepreneurial background |
|
|
| |
| |
.jpeg "David Wehner") |
| |
| David Wehner recently became Senior Investment Manager at SHS |
|
|
|
Business manager and molecular biologist David Wehner strengthens our SHS team with his expertise and experience at the interface between business and life science.
|
|
|
|
|
|
| |
| |
|
|
| |
Farewell to founding partner Reinhilde Spatscheck |
|
|
| |
| |
A long partnership is now drawing to a close. Our founding partner Reinhilde Spatscheck is leaving SHS and going into retirement.
|
|
|
|
|
|
|
|
| |
| |
|
|
| |
J.P. Morgan Healthcare Conference in San Francisco – January 2020 |
|
|
| |
| |
.jpeg "JPM_AZ_PF") |
| |
| The SHS duo of Dr. André Zimmermann and Patrick Frohnheiser in San Francisco |
|
|
|
SHS used one of the leading international healthcare events for active business development with globally leading corporations that are also potential buyers of SHS portfolio firms.
|
|
|
|
|
|
| |
| |
|
|
| |
Sascha Alilovic of SHS on the London podium on the topic of “Exits in Medtech Investments” |
|
|
| |
| |
The MedTech Invest Europe conference was held in London at the end of November 2019. In a forum of leading European MedTech investors SHS partner Sascha Alilovic discussed exit strategies and how to ensure that investors and companies achieve their goals.
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Jobs at Portfolio Companies |
|
|
| |
|
|
| |
| |
|
|
|
|
| |
| |
(Junior) Investment Manager (m/f/d)
Read more »
|
|
| |
Managing Director/MBI candidate (m/f/d) for medical technology, succession solution
Read more »
|
|
| |
Internship for Students
Read more »
|
|
|
| |
| |
|
|
|
|
|
|
|
| |
| |
Handelsblatt, January 30, 2020: “Selfapy psychotherapy app receives six million euros from investors” |
|
| |
The Handelsblatt reports on the digital health company Selfapy, in which the Tübingen-based SHS has participated along with other investors. |
|
| |
Read more » |
|
|
| |
| |
VC Magazin, issue of 12/2019: “It is good that the group of investors has broadened” |
|
| |
VC Magazin interviewed Hubertus Leonhardt and Manfred Ulmer-Weber on the development of SHS and the current fifth fund, “SHS V”. |
|
| |
Read more » |
|
|
| |
| |
transkript, November 27, 2019: “SHS invests in manufacturers of disposable systems” |
|
| |
SHS has invested in the Austrian company Single Use Support GmbH (SUS) of Kufstein. SUS develops and produces systems and consumables that make the handling of large amounts of liquids in the laboratory setting and production easier and more efficient. Thomas Wurm and Johannes Kirchmair founded the company in 2015 and seek to expand sales structures and drive international growth with the aid of SHS capital. |
|
| |
Read more » |
|
|
| |
| |
|
|
| |
|
|
| |
Investment focus
|
|
| |
|
|
| |
| Sector: |
|
life sciences (medical technology, diagnostics, applied technologies, digital health, industrial biotechnology/pharmaceutical industry; no drug development) |
| Geographical Focus: |
|
Germany, Austria, Switzerland, Scandinavia, Benelux |
| Reasons for investment: |
|
growth capital, strengthening equity, MBO/MBI, change of shareholders/succession, M&A financing, spin-off |
| Company situation: |
|
growth/expansion, succession/company sale, internationalization; operating profit may be negative for growth, or for technology-related reasons |
| Transaction value and investment size: |
|
transaction value: up to € 100m; investment amount:
€ 2-30m, with a co-investor from the SHS-network up to € 60m |
| Investment types: |
|
majorities or minorities, equity & financial instruments similar to equity |
|
|
| |
|
|
|
|
|
| |
|
|
| |
The newsletter is published by SHS Gesellschaft für Beteiligungsmanagement mbH
|
|
| |
|
|
| |
Bismarckstrasse 12 | 72072 Tuebingen | Germany | www.shs-capital.eu
Tel +49 7071 9169-0 | Fax +49 7071 9169-190
|
|
| |
|
|
| |
|
Editorial team: SHS Gesellschaft für Beteiligungsmanagement mbH
Design and technical realisation: UNIBRAND GmbH
|
|
To unsubscribe the newsletter, please click here. If you like us to delete your data, please send an email with the subject „data deletion“ to tuebingen@shs-capital.eu.
|
|
|
| |
|
|
|
|
| |
|
.jpeg "medtechzwo")
.jpeg "Tyromotion")
.jpeg "CoreMedic")
.jpeg "MTi")